UCB SA (UCBJF)

Market Cap	54.28B +54.4%
Revenue (ttm)	9.09B +25.8%
Net Income	1.83B +46.3%
EPS	9.43 +46.5%
Shares Out	n/a
PE Ratio	29.67
Forward PE	22.88
Dividend	1.58 (0.52%)
Ex-Dividend Date	Apr 25, 2025

Volume	199
Average Volume	1,337
Open	281.70
Previous Close	292.69
Day's Range	276.21 - 297.49
52-Week Range	150.70 - 345.39
Beta	0.26
RSI	40.72
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1925
• Employees: 9,765
• Stock Exchange: OTCMKTS
• Ticker Symbol: UCBJF

Financial Performance

In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.

Financial numbers in EUR